Ghana airborne geophysics project in the Volta and Keta Basin : BGS final report

This report describes the work undertaken by BGS between November 2006 and March 2009 in collaboration with Fugro Airborne Surveys Pty Ltd on an airborne geophysical survey and ground reconnaissance mapping of the Volta River and Keta Basins, Ghana. The project was supported by the EU as part of the Mining Sector Support Programme, Project Number 8ACP GH 027/13. The initial contract duration was three years, but this was extended by five months to account for acquisition of gravity data by another project. Some parts of Ghana have been airborne surveyed as part of the Mining Sector Development and Environmental Project, co-funded by the World Bank and the Nordic Development Fund, but no work was carried out on the Volta River and Keta basins, which together form a major portion of the Ghanaian territory. The approximate areas covered by the surveys are estimated at 98,000 km² for the satellite imagery and the airborne geophysics, except for the Time Domain Electromagnetic (TDEM) survey which was limited to 60,000 km². The main beneficiary of this project is the Geological Survey Department, GSD. The work enhanced its geological infrastructure and its personnel received hands-on training on modern geological mapping technology. Indirect beneficiaries were the mining and exploration companies that can follow up the reconnaissance work with detailed exploration work. The project was conducted in five phases, and this document reports on the BGS input to Phase 1, 4 and 5, with no inputs required in Phases 2 and 3: • Phase1: geological outline through Radar and optical satellite imageries. • Phase 2: airborne geophysical survey over the two basins for magnetics and Gamma Ray spectrometry (Fugro survey). • Phase 3: airborne electromagnetic and magnetic geophysical survey of specific areas, following the completion and interpretation of phase 2, using fixed wing time domain technology (Fugro survey). • Phase 4: interpretation of the combined geology and geophysics. • Phase 5: production of factual and interpretation maps. The full list of BGS products is outlined in Table 1 below, while Jordan et al. (2006) describe the products delivered on schedule in Phase 1

Microscopic Description of Nuclear Fission at Finite Temperature

While a predictive, microscopic theory of nuclear fission has been elusive, advances in computational techniques and in our understanding of nuclear structure are allowing us to make significant progress. Through nuclear energy density functional theory, we study the fission of thorium and uranium isotopes in detail. These nuclides have been thought to possess hyperdeformed isomers in the third minima of their potential energy surfaces, but microscopic theories tend to estimate either shallow or non- existent third minima in these nuclei. We seek an explanation in terms of neutron shell effects. We study how the fission pathways, the symmetry, and the third minima of these nuclei evolve with increasing excitation energy. We then study the fission of mercury-180, in which a recent experiment unexpectedly discovered that this nucleus fissions asymmetrically. We find that the fission of mercury-180 and mercury-198 is driven by subtleties in shell effects on the approach to scission. We finally survey fission barrier heights and spontaneous fission half-lives of several actinide nuclei, from radium to californium. For a new energy density functional, we find good agreement between our calculations and available experimental data, lending confidence to the predictions of our theory beyond experimentally measured nuclei

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

BACKGROUND: Hospitalization is a costly and distressing event associated with relapse during schizophrenia treatment. No information is available on the predictors of psychiatric hospitalization during maintenance treatment with olanzapine long-acting injection (olanzapine-LAI) or how the risk of hospitalization differs between olanzapine-LAI and oral olanzapine. This study aimed to identify the predictors of psychiatric hospitalization during maintenance treatment with olanzapine-LAI and assessed four parameters: hospitalization prevalence, incidence rate, duration, and the time to first hospitalization. Olanzapine-LAI was also compared with a sub-therapeutic dose of olanzapine-LAI and with oral olanzapine. METHODS: This was a post hoc exploratory analysis of data from a randomized, double-blind study comparing the safety and efficacy of olanzapine-LAI (pooled active depot groups: 405 mg/4 weeks, 300 mg/2 weeks, and 150 mg/2 weeks) with oral olanzapine and sub-therapeutic olanzapine-LAI (45 mg/4 weeks) during 6 months' maintenance treatment of clinically stable schizophrenia outpatients (n=1064). The four psychiatric hospitalization parameters were analyzed for each treatment group. Within the olanzapine-LAI group, patients with and without hospitalization were compared on baseline characteristics. Logistic regression and Cox's proportional hazards models were used to identify the best predictors of hospitalization. Comparisons between the treatment groups employed descriptive statistics, the Kaplan-Meier estimator and Cox's proportional hazards models. RESULTS: Psychiatric hospitalization was best predicted by suicide threats in the 12 months before baseline and by prior hospitalization. Compared with sub-therapeutic olanzapine-LAI, olanzapine-LAI was associated with a significantly lower hospitalization rate (5.2% versus 11.1%, p < 0.01), a lower mean number of hospitalizations (0.1 versus 0.2, p = 0.01), a shorter mean duration of hospitalization (1.5 days versus 2.9 days, p < 0.01), and a similar median time to first hospitalization (35 versus 60 days, p = 0.48). Olanzapine-LAI did not differ significantly from oral olanzapine on the studied hospitalization parameters. CONCLUSIONS: In clinically stable schizophrenia outpatients receiving olanzapine-LAI maintenance treatment, psychiatric hospitalization was best predicted by a history of suicide threats and prior psychiatric hospitalization. Olanzapine-LAI was associated with a significantly lower incidence of psychiatric hospitalization and shorter duration of hospitalization compared with sub-therapeutic olanzapine-LAI. Olanzapine-LAI did not differ significantly from oral olanzapine on hospitalization parameters

Cosmological perturbations on local systems

We study the effect of cosmological expansion on orbits--galactic, planetary, or atomic--subject to an inverse-square force law. We obtain the laws of motion for gravitational or electrical interactions from general relativity--in particular, we find the gravitational field of a mass distribution in an expanding universe by applying perturbation theory to the Robertson-Walker metric. Cosmological expansion induces an ($\ddot a/a) \vec r$ force where $a(t)$ is the cosmological scale factor. In a locally Newtonian framework, we show that the $(\ddot a/a) \vec r$ term represents the effect of a continuous distribution of cosmological material in Hubble flow, and that the total force on an object, due to the cosmological material plus the matter perturbation, can be represented as the negative gradient of a gravitational potential whose source is the material actually present. We also consider the effect on local dynamics of the cosmological constant. We calculate the perihelion precession of elliptical orbits due to the cosmological constant induced force, and work out a generalized virial relation applicable to gravitationally bound clusters.Comment: 10 page

Reflections on the value of autistic participation in a tri‐national teacher‐training project through discourses of acceptance, othering and power

The Transform Autism Education (TAE) project is a tri‐national teacher training scheme involving Greece, Italy and the UK, whose purpose is to set up training projects to facilitate the educational inclusion of autistic children. Running over three years from 2014 to 2017, the involvement of autistic participants has been the source of some discussion. Here, TAE team members Wood and Milton reflect on narratives of participation, acceptance and struggle which emerged during a workshop they ran in Greece. Derived from 11 non‐autistic and two autistic participants, and analysed via discourse analysis, these stories suggest a high value placed on autistic participation by non‐autistic TAE team members, but an unwitting tendency to ‘other’ autistic people and a lack of awareness of the power differential. Meanwhile, as the autistic team members describe how educational and social participation can be achieved, the implications for autism education researchers and practitioners are discussed

ReseArch with Patient and Public invOlvement: a RealisT evaluation - the RAPPORT study

Background Patient and public involvement (PPI) is a prerequisite for many funding bodies and NHS research ethics approval. PPI in research is defined as research carried out with or by the public rather than to, about or for them. While the benefits of PPI have been widely discussed, there is a lack of evidence on the impact and outcomes of PPI in research. Objectives To determine the types of PPI in funded research, describe key processes, analyse the contextual and temporal dynamics of PPI and explore the experience of PPI in research for all those involved. Mechanisms contributing to the routine incorporation of PPI in the research process were assessed, the impact of PPI on research processes and outcomes evaluated, and barriers and enablers to effective PPI identified. Design A three-staged realist evaluation drawing on Normalisation Process Theory to understand how far PPI was embedded within health-care research in six areas: diabetes mellitus, arthritis, cystic fibrosis, dementia, public health and learning disabilities. The first two stages comprised a scoping exercise and online survey to chief investigators to assess current PPI activity. The third stage consisted of case studies tracked over 18 months through interviews and document analysis. The research was conducted in four regions of England. Participants Non-commercial studies currently running or completed within the previous 2 years eligible for adoption on the UK Clinical Research Network portfolio. A total of 129 case study participants included researchers and PPI representatives from 22 research studies, and representatives from funding bodies and PPI networks